The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
BRAF Mutation in Papillary Thyroid Carcinoma in a Japanese Population: Its Lack of Correlation with High-Risk Clinicopathological Features and Disease-Free Survival of Patients
Open accessAbstract
Recent studies have demonstrated that BRAF(V600E) mutation is a common event in papillary thyroid carcinoma and a majority of these lesions have shown a direct relationship between BRAF(V600E) mutation and aggressive characteristics, including a worse patient prognosis. However, there are no studies from Japan regarding this issue in a large series with adequate postoperative follow-up periods. We investigated BRAF(V600E) mutation in 631 patients with papillary carcinoma having median follow-up periods of 83 months. The prevalence of BRAF(V600E) mutation was 38.4%, and the rate was higher in carcinoma larger than 1.0 cm but did not successively increase with tumor size. Furthermore, the prevalence did not significantly increase in cases demonstrating high-risk biological features such as clinically apparent lymph node metastasis, massive extrathyroid extension, advanced age, distant metastasis at surgery, and advanced Stage. The disease-free survival of patients with BRAF(V600E) mutation did not differ from that of those without BRAF(V600E) mutation. These findings indicate that, although BRAF(V600E) mutation may play some roles in local carcinoma development, there is no evidence that BRAF(V600E) mutation significantly reflects the aggressive characteristics and poor prognosis of patients with papillary carcinoma in Japan.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TNM Classification of Malignant Tumours
(1987) · Springer eBooks · doi:10.1007/978-3-642-82982-6 · Cited by 16,049
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
TNM Classification of Malignant Tumours
(2003) · John Wiley & Sons, Inc. eBooks · doi:10.1002/0471463752 · Cited by 3,946
Mitogen-activated protein kinase pathways
Robinson, M. J., & Cobb, M. H. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80061-0 · Cited by 2,474
BRAF and RAS mutations in human lung cancer and melanoma.
Brose, M. S., Volpe, P., Feldman, M. D., Kumar, M. S., Rishi, I., Gerrero, R. M., Einhorn, E., Herlyn, M., Minna, J. D., Nicholson, A. G., et al. (2002) · PubMed · Cited by 1,048
Nikiforova, M. N., Kimura, E. T., Gandhi, M., Biddinger, P. W., Knauf, J. A., Basolo, F., Zhu, Z., Giannini, R., Salvatore, G., Fusco, A., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030838 · Cited by 1,042
BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer
Xing, M., Westra, W. H., Tufano, R. P., Cohen, Y., Rosenbaum, E., Rhoden, K. J., Carson, K. A., Vasko, V., Larin, A., Tallini, G., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0987 · Cited by 993
Garnett, M. J., & Marais, R. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.022 · Cited by 799
Clinical Implication of Hot Spot BRAF Mutation, V599E, in Papillary Thyroid Cancers
Namba, H., Nakashima, M., Hayashi, T., Hayashida, N., Maeda, S., Rogounovitch, T. I., Ohtsuru, A., Saenko, V. A., Kanematsu, T., & Yamashita, S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030305 · Cited by 533
Adeniran, A. J., Zhu, Z., Gandhi, M., Steward, D. L., Fidler, J. P., Giordano, T. J., Biddinger, P. W., & Nikiforov, Y. E. (2006) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000176432.73455.1b · Cited by 495
The Prevalence and Prognostic Value of BRAF Mutation in Thyroid Cancer
Kebebew, E., Weng, J., Bauer, J., Ranvier, G., Clark, O. H., Duh, Q.-Y., Shibru, D., Bastian, B., & Griffin, A. (2007) · Annals of Surgery · doi:10.1097/sla.0b013e318148563d · Cited by 480
Raf proteins and cancer: B-Raf is identified as a mutational target
Mercer, K. E., & Pritchard, C. A. (2003) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(03)00016-7 · Cited by 457
Sakamoto, A., Kasai, N., & Sugano, H. (1983) · Cancer · doi:10.1002/1097-0142(19831115)52:10<1849::aid-cncr2820521015>3.0.co;2-x · Cited by 438
Targeting the ERK signaling pathway in cancer therapy
Kohno, M., & Pouyssegur, J. (2006) · Annals of Medicine · doi:10.1080/07853890600551037 · Cited by 416
Yuen, S. T., Davies, H. R., Chan, T. L., Ho, J. W. C., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Tsui, W. W., Chan, A. S. Y., et al. (2002) · PubMed · Cited by 404
Lupi, C., Giannini, R., Ugolini, C., Proietti, A., Berti, P., Minuto, M., Materazzi, G., Elisei, R., Santoro, M., Miccoli, P., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1179 · Cited by 391
Riesco-Eizaguirre, G., Gutiérrez-Martínez, P., García-Cabezas, M. A., Nistal, M., & Santisteban, P. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01119 · Cited by 376
Zhu, Z., Gandhi, M., Nikiforova, M. N., Fischer, A. H., & Nikiforov, Y. E. (2003) · American Journal of Clinical Pathology · doi:10.1309/nd8d-9laj-trct-g6qd · Cited by 371
BRAF mutations are associated with some histological types of papillary thyroid carcinoma
Trovisco, V., Vieira de Castro, I., Soares, P., Máximo, V., Silva, P., Magalhães, J., Abrosimov, A., Guiu, X. M., & Sobrinho‐Simões, M. (2004) · The Journal of Pathology · doi:10.1002/path.1511 · Cited by 363
Zhu, Z., Gandhi, M., Nikiforova, M. N., Fischer, A. H., & Nikiforov, Y. E. (2003) · American Journal of Clinical Pathology · doi:10.1309/nd8d9lajtrctg6qd · Cited by 355
BRAF mutations in papillary carcinomas of the thyroid
Fukushima, T., Suzuki, S., Mashiko, M., Ohtake, T., Endo, Y., Takebayashi, Y., Sekikawa, K., Hagiwara, K., & Takenoshita, S. (2003) · Oncogene · doi:10.1038/sj.onc.1206739 · Cited by 297
Prognostic Implications of the Tall Cell Variant of Papillary Thyroid Carcinoma
Johnson, T. L., Lloyd, R. V., Thompson, N. W., Beierwaltes, W. H., & Sisson, J. C. (1988) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198801000-00003 · Cited by 294
Missense mutations of the BRAF gene in human lung adenocarcinoma.
Naoki, K., Chen, T. H., Richards, W. G., Sugarbaker, D. J., & Meyerson, M. M. (2002) · PubMed · Cited by 287
Ito, Y., Tomoda, C., Uruno, T., Takamura, Y., Miya, A., Kobayashi, K., Matsuzuka, F., Kuma, K., & Miyauchi, A. (2006) · World Journal of Surgery · doi:10.1007/s00268-005-0270-z · Cited by 264
Self-citationControl of the ERK MAP kinase cascade by Ras and Raf.
Marais, R., & Marshall, C. (1996) · PubMed · Cited by 246
Kim, T. Y., Kim, W. B., Rhee, Y. S., Song, J. Y., Kim, J. M., Gong, G., Lee, S., Kim, S. Y., Kim, S. C., Hong, S. J., et al. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02605.x · Cited by 238
Fugazzola, L., Puxeddu, E., Avenia, N., Romei, C., Cirello, V, Cavaliere, A., Faviana, P., Mannavola, D., Moretti, S., Rossi, S., et al. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01086 · Cited by 237
Mutations of the BRAF Gene in Papillary Thyroid Carcinoma in a Korean Population
Kim, K. H., Kang, D. W., Kim, S. H., Seong, I. O., & Kang, D. Y. (2004) · Yonsei Medical Journal · doi:10.3349/ymj.2004.45.5.818 · Cited by 229
Kim, T. Y., Kim, W. B., Song, J. Y., Rhee, Y. S., Gong, G., Cho, Y. M., Kim, S. Y., Kim, S. C., Hong, S. J., & Shong, Y. K. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02389.x · Cited by 221
BRAF mutations in an Italian cohort of thyroid cancers
Fugazzola, L., Mannavola, D., Cirello, V., Vannucchi, G., Muzza, M., Vicentini, L., & Beck‐Peccoz, P. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02089.x · Cited by 184
A therapeutic strategy for incidentally detected papillary microcarcinoma of the thyroid
Ito, Y., & Miyauchi, A. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0428 · Cited by 175
Self-citationIto, Y., Tomoda, C., Uruno, T., Takamura, Y., Miya, A., Kobayashi, K., Matsuzuka, F., Kuma, K., & Miyauchi, A. (2005) · World Journal of Surgery · doi:10.1007/s00268-005-7789-x · Cited by 170
Self-citationPrognostic Factors and Therapeutic Strategies for Differentiated Carcinomas of the Thyroid
ITO, Y., & MIYAUCHI, A. (2009) · Endocrine Journal · doi:10.1507/endocrj.k08e-166 · Cited by 159
Self-citationMitogen-Activated Protein Kinases in Cell-Cycle Control
MacCorkle, R. A., & Tan, T. (2005) · Cell Biochemistry and Biophysics · doi:10.1385/cbb:43:3:451 · Cited by 130
Prevalence and prognostic significance of tall cell variant of papillary thyroid carcinoma
Michels, J. J., Jacques, M., Henry-Amar, M., & Bardet, S. (2006) · Human Pathology · doi:10.1016/j.humpath.2006.08.001 · Cited by 128
Regulatory Mechanisms and Function of ERK MAP Kinases
Torii, S. (2004) · The Journal of Biochemistry · doi:10.1093/jb/mvh159 · Cited by 125
Vasko, V. V., Hu, S., Wu, G., Xing, J. C., Ларін, О. С., Savchenko, V., Trink, B., & Xing, M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2353 · Cited by 121
Ito, Y., Hirokawa, M., Fukushima, M., Inoue, H., Yabuta, T., Uruno, T., Kihara, M., Higashiyama, T., Takamura, Y., Miya, A., et al. (2008) · World Journal of Surgery · doi:10.1007/s00268-007-9406-7 · Cited by 99
Self-citationLymphatic Mapping Establishes the Role of BRAF Gene Mutation in Papillary Thyroid Carcinoma
Kim, J., Giuliano, A. E., Turner, R. R., Gaffney, R., Umetani, N., Kitago, M., Elashoff, D. A., & Hoon, D. S. �. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000224751.80858.13 · Cited by 79
Rodolico, V., Cabibi, D., Pizzolanti, G., Richiusa, P., Gebbia, N., Martorana, A., Russo, A. D., Amato, M. C., Galluzzo, A., & Giordano, C. S. D. S. (2007) · Cancer · doi:10.1002/cncr.22912 · Cited by 79
Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto's thyroiditis
Kim, K., Suh, K., Kang, D., & Kang, D. (2005) · Pathology International · doi:10.1111/j.1440-1827.2005.01866.x · Cited by 71
BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas
Lee, J. H., Lee, E. S., Kim, Y., Won, N. H., & Chae, Y. (2006) · Pathology · doi:10.1080/00313020600696264 · Cited by 60
Caveolin-1 and 14-3-3 sigma expression in follicular variant of thyroid papillary carcinoma
Ito, Y., Yoshida, H., Tomoda, C., Uruno, T., Takamura, Y., Miya, A., Kobayashi, K., Matsuzuka, F., Nakamura, Y., Kakudo, K., et al. (2005) · Pathology - Research and Practice · doi:10.1016/j.prp.2005.08.002 · Cited by 16
Self-citation
Cited by
Kim, T. H., Park, Y. J., Lim, J. A., Ahn, H. Y., Lee, E. K., Lee, Y. J., Kim, K. W., Hahn, S. K., Youn, Y. K., Kim, K. H., et al. (2012) · Cancer · doi:10.1002/cncr.26500 · Cited by 400
Tufano, R. P., Teixeira, G. V., Bishop, J., Carson, K. A., & Xing, M. (2012) · Medicine · doi:10.1097/md.0b013e31826a9c71 · Cited by 302
Low-risk papillary microcarcinoma of the thyroid: A review of active surveillance trials
Ito, Y., Miyauchi, A., & Oda, H. (2018) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2017.03.004 · Cited by 295
Self-citationLi, C., Lee, K. C., Schneider, E. B., & Zeiger, M. A. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2104 · Cited by 275
Metadata
- Authors
- ITO, Y., YOSHIDA, H., MARUO, R., MORITA, S., TAKANO, T., HIROKAWA, M., YABUTA, T., FUKUSHIMA, M., INOUE, H., TOMODA, C., KIHARA, M., URUNO, T., HIGASHIYAMA, T., TAKAMURA, Y., MIYA, A., KOBAYASHI, K., MATSUZUKA, F., & MIYAUCHI, A.
- Venue
- Endocrine Journal
- Publisher
- Japan Endocrine Society
- Published
- 2009
- Volume
- 56
- Issue
- 1
- Pages
- 89-97
- ISSN
- 0918-8959 (ISSN-L)
- 1348-4540
- OpenAlex
- W1965481481
- Cited by
- 255
- References
- 43
- FWCI
- 13.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.